Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
Journal
Journal of Gastroenterology and Hepatology (Australia)
Journal Volume
33
Journal Issue
3
Pages
710-717
Date Issued
2018
Abstract
Background and Aim: The real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) remain limited for East Asian hepatitis C virus genotype 1b (HCV-1b) patients. The study aimed to evaluate the antiviral responses of PrOD-based regimens for HCV-1b patients in Taiwan. Methods: The study performed a retrospective analysis of 103 HCV-1b patients receiving PrOD with or without ribavirin (RBV) for 12?weeks. Data were analyzed to assess the on-treatment and off-therapy HCV viral load and on-treatment adverse events. The pre-specified characteristics related to sustained virologic response 12?weeks off therapy (SVR12) were compared. Results: At treatment week 4, 100 of 102 patients (98.0%) had serum HCV RNA level
SDGs
Other Subjects
alanine aminotransferase; aspartate aminotransferase; bilirubin; bilirubin glucuronide; dasabuvir; hepatitis B surface antigen; ombitasvir plus paritaprevir plus ritonavir; ribavirin; robatrol; virus RNA; ABT-267; ABT-333; ABT-450; anilide; antivirus agent; carbamic acid derivative; macrocyclic compound; ribavirin; ritonavir; sulfonamide; uracil; acute kidney failure; adult; aged; alanine aminotransferase blood level; antiviral therapy; arthralgia; Article; ascites; aspartate aminotransferase blood level; body mass; body weight gain; chronic hepatitis C; coughing; decompensated liver cirrhosis; diarrhea; drug efficacy; drug safety; drug withdrawal; dyspnea; fatigue; female; headache; Hepatitis C virus subtype 1b; human; hyperbilirubinemia; insomnia; kidney function; liver cell carcinoma; liver cirrhosis; liver fibrosis; major clinical study; male; nausea; priority journal; pruritus; retrospective study; side effect; sustained virologic response; Taiwan; treatment duration; treatment interruption; very elderly; virus load; analogs and derivatives; chronic hepatitis C; combination drug therapy; genetics; genotype; Hepacivirus; middle aged; safety; treatment outcome; virology; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Macrocyclic Compounds; Male; Middle Aged; Retrospective Studies; Ribavirin; Ritonavir; Safety; Sulfonamides; Taiwan; Treatment Outcome; Uracil; Viral Load
Publisher
Blackwell Publishing
Type
journal article